Dr. Miller is a vitreo-retinal surgeon in the Ophthalmology Department's Retina Service. Based at Mass. Eye and Ear's Charles Street campus, Dr. Miller has widely recognized expertise in age-related macular degeneration and diabetic retinopathy.
- Clinical Interests
- Diseases of the retina and vitreous
- Age-related macular degeneration (AMD)
- Diabetic retinopathy
- Photodynamic therapy
- Medical Education
- MD, Harvard Medical School
- Residency, Massachusetts Eye and Ear Infirmary
- Fellowship, Massachusetts Eye and Ear Infirmary
- Board Certifications
- Boston: Massachusetts Eye and Ear Infirmary
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Harvard Pilgrim Health Plan - other
- Senior Whole Health
- Tufts Health Plan
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
Dr. Miller is a vitreo-retinal surgeon in the Ophthalmology Department's Retina Service, located at Mass. Eye and Ear's main campus on Charles Street. She is the chief of service at Mass. Eye and Ear as well as at Mass. General Hospital, chair of the Harvard Medical School Department of Ophthalmology, and director of the Mass. Eye and Ear Angiogenesis Laboratory. A graduate of Massachusetts Institute of Technology and Harvard Medical School, she completed her Ophthalmology residency and Retina fellowship training at Mass. Eye and Ear. A member of the full time faculty of Harvard Medical School, Dr. Miller is the David Glendenning Cogan Professor of Ophthalmology.
Dr. Miller's clinical and research interests focus on age-related macular degeneration and diabetic retinopathy. She and her colleagues at Mass. Eye and Ear pioneered the development of novel therapies that were able to reduce, slow and, in some cases, reverse vision loss in patients.
An internationally recognized expert in the field of macular degeneration, Dr. Miller has published more than 100 peer-reviewed papers, 45 book chapters and review articles, is co-editor of Albert and Jakobiec's Principles and Practice of Ophthalmology, and is a named inventor on six U.S. patents. She has received numerous awards from professional and research associations.
- Research Summary
- Dr. Miller is the director of the Mass. Eye and Ear's Angiogenesis Laboratory. Her research interests focus on ocular neovascularization, particularly as it relates to age-related macular degeneration (AMD) and diabetic retinopathy, including the molecular mechanisms of angiogenesis and neuroprotection, the development of effective therapies, and drug delivery. She and her colleagues at Mass. Eye and Ear pioneered the development of Verteporfin photodynamic therapy (PDT or Visudyne), the first pharmacologic therapy which was able to reduce and slow vision loss in patients with AMD. The group also identified the importance of vascular endothelial growth factor (VEGF) in neovascular AMD, and helped develop anti-VEGF therapies - pegaptanib and ranibizumab - the latter able to improve vision in about one third of patients with neovascular AMD. While these therapies have improved the outlook for patients with AMD, Dr. Miller and her colleagues continue investigations to elucidate the pathophysiology and improve therapies for AMD.
Dr. Miller has published more than 100 peer-reviewed papers, 45 book chapters and review articles, is co-editor of Albert and Jakobiec's Third Edition Principles and Practice of Ophthalmology. She is an invited speaker at professional and academic events on a regular basis.
A phase I/II clinical trial at Massachusetts Eye and Ear found that some patients taking high doses of a cholesterol-lowering medication had complete resolution of lipid deposits in the dry form of age-related macular degeneration, the leading cause of blindness in the developed world,
243 Charles Street
Boston, MA 02114 - 3002